Lv52
810 积分 2023-10-16 加入
Sample Size for Enriched Biomarker Designs With Measurement Error for Time-to-Event Outcomes
19小时前
已完结
Mediation Analysis of Path‐Specific Effects in Randomised Clinical Trials With Repeatedly Measured Mediators and Outcomes
19小时前
已完结
Multiplicity for a group sequential trial with biomarker subpopulations
8天前
已关闭
A unified framework for weighted parametric group sequential design
9天前
已完结
Consideration of stratification in confirmatory trials with time-to-event endpoint
18天前
已完结
A General Approach for Sample Size Calculation With Nonproportional Hazards and Cure Rates
18天前
已完结
Population-adjusted unanchored indirect comparisons of cancer therapies with borrowing of pan-tumor information
24天前
已完结
Bayesian dynamic power prior borrowing for augmenting a control arm for survival analysis
1个月前
已关闭
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
1个月前
已完结
Estimating the Variance of Covariate‐Adjusted Estimators of Average Treatment Effects in Clinical Trials With Binary Endpoints
1个月前
已完结
皖公网安备34019202002308
